TOCA vs. VBIV, NERV, BNTC, ORGS, HUGE, KALA, TLPH, COCP, NRSN, and FLGC
Should you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include VBI Vaccines (VBIV), Minerva Neurosciences (NERV), Benitec Biopharma (BNTC), Orgenesis (ORGS), FSD Pharma (HUGE), KALA BIO (KALA), Talphera (TLPH), Cocrystal Pharma (COCP), NeuroSense Therapeutics (NRSN), and Flora Growth (FLGC). These companies are all part of the "medical" sector.
Tocagen (NASDAQ:TOCA) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.
VBI Vaccines has a net margin of -1,069.29% compared to Tocagen's net margin of -176,433.34%. VBI Vaccines' return on equity of -234.77% beat Tocagen's return on equity.
In the previous week, VBI Vaccines had 4 more articles in the media than Tocagen. MarketBeat recorded 4 mentions for VBI Vaccines and 0 mentions for Tocagen. VBI Vaccines' average media sentiment score of 0.20 beat Tocagen's score of 0.00 indicating that VBI Vaccines is being referred to more favorably in the news media.
Tocagen has higher earnings, but lower revenue than VBI Vaccines. Tocagen is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.
21.4% of Tocagen shares are owned by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are owned by institutional investors. 10.9% of Tocagen shares are owned by insiders. Comparatively, 10.4% of VBI Vaccines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
VBI Vaccines received 257 more outperform votes than Tocagen when rated by MarketBeat users. Likewise, 74.85% of users gave VBI Vaccines an outperform vote while only 66.03% of users gave Tocagen an outperform vote.
Tocagen has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500.
Summary
VBI Vaccines beats Tocagen on 10 of the 15 factors compared between the two stocks.
Get Tocagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
